Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ).
Shanghai Fosun Pharmaceutical has announced the first grant under its 2025 H Share Restricted Stock Unit (RSU) Scheme, which was approved by shareholders. The grant involves 195 eligible employees, including key executives, receiving a total of 10,589,500 RSUs. This initiative is part of the company’s strategy to incentivize and retain talent, potentially impacting its operational efficiency and market competitiveness.
The most recent analyst rating on (HK:2196) stock is a Sell with a HK$26.50 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock company incorporated in China, operating in the pharmaceutical industry. The company focuses on the development, manufacturing, and distribution of pharmaceutical products, medical devices, and healthcare services.
Average Trading Volume: 9,801,390
Technical Sentiment Signal: Buy
Current Market Cap: HK$80.19B
For a thorough assessment of 2196 stock, go to TipRanks’ Stock Analysis page.